SMARCA4 deficiency was shown to be synthetically lethal with CDK4/6 inhibition in NSCLC, and CDK4/6 inhibitors may be effective in this significant subgroup of NSCLC patients (Xue et al., 2019). This evidence concerns the gene CDK4 and non-small cell lung carcinoma.